Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Capecitabine in High-Risk Pseudomyxoma Peritonei After CRS and HIPEC
2018-000655-40Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in pseudomyxoma peritonei (PMP) and malignant peritoneal neoplasm, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
capecitabine
03
Conditions
pseudomyxoma peritonei (PMP)malignant peritoneal neoplasm
Beyond the preview
Go deeper on 2018-000655-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000655-40.